LENZ LENZ Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815776 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-29.4%
TTM net income YoY-138.2%
TTM EPS YoY-119.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin82.0%
Operating margin-1,211.2%
Net margin-1,135.0%
FCF margin-1,033.3%
EBITDA margin-1,207.6%
Returns
ROE-72.7%
ROA-66.7%
ROIC (approx.)-71.7%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets8.5%
Debt / equity0.00x
Current ratio11.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $19.09M | $0 |
| Cost of revenue | $418,000 | $0 |
| Gross profit | $18.67M | $0 |
| R&D expense | $18.67M | $29.80M |
| SG&A expense | $91.14M | $28.81M |
| Operating income | -$91.14M | -$58.61M |
| Pretax income | -$81.62M | -$49.77M |
| Income tax | $502,000 | $1,000 |
| Net income | -$82.13M | -$49.77M |
| EBITDA | -$90.85M | -$58.55M |
| EPS (basic) | -2.85 | -2.34 |
| EPS (diluted) | -2.85 | -2.34 |
| Weighted avg. shares (diluted) | 28.81M | 21.28M |
| Balance sheet | ||
| Cash & equivalents | $25.18M | $20.16M |
| Receivables | $329,000 | $0 |
| Inventory | $2.94M | $0 |
| Current assets | $301.41M | $211.92M |
| PP&E, net | $1.19M | $651,000 |
| Total assets | $305.88M | $215.30M |
| Current liabilities | $21.19M | $10.41M |
| Total liabilities | $21.54M | $11.22M |
| Shareholders' equity | $284.34M | $204.08M |
| Shares outstanding | 31.34M | 27.52M |
| Cash flow statement | ||
| Operating cash flow | -$69.17M | -$59.39M |
| Capital expenditure | $827,000 | $468,000 |
| Free cash flow | -$70.00M | -$59.86M |
| Investing cash flow | -$75.67M | -$154.48M |
| Financing cash flow | $149.75M | $199.00M |
| Depreciation & amortization | $287,000 | $58,000 |
| Stock-based compensation | $12.55M | $6.37M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.